|
| Interactions: | Acenocoumarol
Adverse Effect: Increased risk of bleeding and hematoma when neuraxial anesthesia is employed Clinical Management: Acenocoumarol should be discontinued prior to the initiation of therapy with Ardeparin . If this is not possible, patients receiving Acenocoumarol and Ardeparin concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to Ardeparin therapy
Celecoxib
Adverse Effect: an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed Clinical Management: Patients receiving Ardeparin and Celecoxib should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to Ardeparin . Celecoxib should be discontinued several days prior to surgery.
Dipyridamole
Adverse Effect: Increased risk of bleeding and hematoma when neuraxial anesthesia is employed Clinical Management: Drugs which affect hemostasis should be discontinued prior to the initiation of therapy with Ardeparin or heparinoid. If this is not possible, patients receiving Ardeparin or heparinoid and Dipyridamole concurrently should be monitored closely for bleeding, which may be serious.
Flurbiprofen
Adverse Effect: an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed Clinical Management: Patients receiving Ardeparin and Flurbiprofen concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to Ardeparin . Flurbiprofen should be discontinued several days prior to surgery.
Ibuprofen
Adverse Effect: an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed Clinical Management: Patients receiving Ardeparin and Ibuprofen should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to Ardeparin . Ibuprofen should be discontinued several days prior to surgery.
Indomethacin
Adverse Effect: an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed Clinical Management: Patients receiving Ardeparin and Indomethacin should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to Ardeparin . Indomethacin should be discontinued several days prior to surgery.
Ketoprofen
Adverse Effect: an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed Clinical Management: Patients receiving Ardeparin and Ketoprofen should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to Ardeparin . Ketoprofen should be discontinued several days prior to surgery.
Ketorolac
Adverse Effect: an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed Clinical Management: Patients receiving Ardeparin and Ketorolac should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to Ardeparin . Ketorolac should be discontinued several days prior to surgery.
Mefenamic Acid
Adverse Effect: an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed Clinical Management: Patients receiving Ardeparin and Mefenamic Acid should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to Ardeparin . Mefenamic Acid should be discontinued several days prior to surgery.
Meloxicam
Adverse Effect: an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed Clinical Management: Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.
Nabumetone
Adverse Effect: an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed Clinical Management: Patients receiving Ardeparin and Nabumetone should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to Ardeparin . Nabumetone should be discontinued several days prior to surgery.
Naproxen
Adverse Effect: an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed Clinical Management: Patients receiving Ardeparin and Naproxen should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to Ardeparin . Naproxen should be discontinued several days prior to surgery.
Nimesulide
Adverse Effect: an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed Clinical Management: Patients receiving Ardeparin and Nimesulide should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to Ardeparin . Nimesulide should be discontinued several days prior to surgery.
Oxyphenbutazone
Adverse Effect: an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed Clinical Management: Patients receiving Ardeparin and Oxyphenbutazone should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to Ardeparin . Oxyphenbutazone should be discontinued several days prior to surgery.
Paracetamol
Adverse Effect: an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed Clinical Ardeparin and Paracetamol should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to Ardeparin . Paracetamol should be discontinued several days prior to surgery.
Phenacetin
Adverse Effect: an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed Clinical Management: Patients receiving Ardeparin and Phenacetin should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to Ardeparin . Phenacetin should be discontinued several days prior to surgery.
Phenindione
Adverse Effect: Increased risk of bleeding and hematoma when neuraxial anesthesia is employed Clinical Management: Phenindione should be discontinued prior to the initiation of therapy with Ardeparin . If this is not possible, patients receiving Ardeparin and Phenindione concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to Ardeparin therapy
Phenylbutazone
Adverse Effect: an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed Clinical Management: Patients receiving Ardeparin and Phenylbutazone should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to Ardeparin . Phenylbutazone should be discontinued several days prior to surgery.
Piroxicam
Adverse Effect: an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed Clinical Management: Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.
Tenoxicam
Adverse Effect: an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed Clinical Management: Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.
Warfarin
Adverse Effect: Increased risk of bleeding and hematoma when neuraxial anesthesia is employed Clinical Management: Warfarin should be discontinued prior to the initiation of therapy with Ardeparin. If this is not possible, patients receiving Ardeparin and Warfarin concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to Ardeparin therapy |
|
|